|
Variate
|
Number of patients [cases (%)]
|
|---|
|
Sex
| |
|
Male
|
119 (60.4)
|
|
Female
|
78 (39.6)
|
| Age ⩾ 60 years |
48 (24.4)
|
|
Ann Arbor stage
| |
|
I
|
31 (15.7)
|
|
II
|
49 (24.9)
|
|
III
|
42 (21.3)
|
|
IV
|
75 (38.1)
|
|
IPI
| |
|
Low (0 or 1)
|
91 (46.2)
|
|
Low/intermediate (2)
|
36 (18.3)
|
|
High/intermediate (3)
|
15 (22.8)
|
|
High (4 or 5)
|
25 (12.7)
|
|
Chemotherapy
| |
|
R-CHOP-14
|
28 (14.2)
|
|
R-CHOP-21
|
169 (85.8)
|
- IPI, International Prognostic Index; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP-14, R-CHOP regimen administered with a 14-day interval; R-CHOP-21, R-CHOP regimen administered with a 21-day interval
